

Se-Hoon Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6806906/publications.pdf>

Version: 2024-02-01

152
papers

9,005
citations

38742

50
h-index

48315

88
g-index

153
all docs

153
docs citations

153
times ranked

13058
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene essentiality for tumour growth influences neoantigen-directed immunoeediting. <i>Clinical and Translational Medicine</i> , 2022, 12, e714.	4.0	0
2	Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 541.	2.9	1
3	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	1.6	94
4	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
5	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281.	1.2	8
6	Synthetic lethality-mediated precision oncology via the tumor transcriptome. <i>Cell</i> , 2021, 184, 2487-2502.e13.	28.9	60
7	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. <i>EPMA Journal</i> , 2021, 12, 629-645.	6.1	0
8	Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. <i>Cancers</i> , 2021, 13, 6050.	3.7	3
9	Junction Location Identifier (JuLI). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 304-318.	2.8	6
10	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Medicine</i> , 2020, 161, 105853.	2.9	23
11	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	2.6	5
12	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
13	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
14	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020, 10, 13231.	3.3	11
15	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	1.1	60
16	Regulatory (FoxP3+) T cells and TGF- β 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	3.3	52
17	MDSC subtypes and CD39 expression on CD8 ⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	2.9	57
18	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9

#	ARTICLE	IF	CITATIONS
19	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	4.1	26
20	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	12.8	34
21	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 446-454.	6.4	75
22	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	12.8	263
23	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	1.1	104
24	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	2.0	38
25	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 751-e231.	3.7	21
26	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	5.1	26
27	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 408-412.	3.0	15
28	Integrin β 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 4162-4174.	7.0	13
29	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	2.0	10
30	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018, 13, e0189766.	2.5	46
31	Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC. <i>Lancet Respiratory Medicine</i> , 2017, 5, e10.	10.7	0
32	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137
33	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	3.0	26
34	Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. <i>Journal of Korean Medical Science</i> , 2017, 32, 415.	2.5	8
35	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. <i>Journal of Pathology</i> , 2017, 243, 307-319.	4.5	63
36	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38

#	ARTICLE	IF	CITATIONS
37	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016, 16, 46.	1.4	14
38	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
39	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1189-1194.	1.1	26
40	IDH2 mutation in gliomas including novel mutation. <i>Neuropathology</i> , 2015, 35, 236-244.	1.2	19
41	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 555-563.	3.0	49
42	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0133371.	2.5	7
43	Mechanisms of Acquired Resistance to AZD9291. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1736-1744.	1.1	202
44	Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy: Differentiation of True Progression from Pseudoprogression with Quantitative Dynamic Contrast-enhanced MR Imaging. <i>Radiology</i> , 2015, 274, 830-840.	7.3	102
45	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , 2015, 20, 1119-1120.	3.7	20
46	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
47	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 182-188.	3.0	3
48	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. <i>PLoS ONE</i> , 2014, 9, e113587.	2.5	15
49	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. <i>Journal of Korean Medical Science</i> , 2014, 29, 1094.	2.5	22
50	Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 980.	2.5	67
51	Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 237-245.	1.1	40
52	Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. <i>Oncotarget</i> , 2014, 5, 3399-3407.	1.8	50
53	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 40.	1.7	31
54	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014, 46, 323-330.	3.0	21

#	ARTICLE	IF	CITATIONS
55	Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. <i>Journal of Neuro-Oncology</i> , 2013, 112, 427-435.	2.9	18
56	The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 277-283.	2.9	21
57	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
58	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2242-2249.	1.5	12
59	Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 51-61.	2.8	63
60	Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS ² -MLPA in patients with glioblastoma multiforme. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 351-358.	3.4	42
61	Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. <i>Clinical Lung Cancer</i> , 2013, 14, 383-389.	2.6	63
62	Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1445-1450.	1.1	65
63	Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-Value Diffusion-weighted Imaging. <i>Radiology</i> , 2013, 269, 831-840.	7.3	147
64	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1069-1074.	1.1	110
65	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 415-422.	1.1	147
66	Application of Cancer Genomics to Solve Unmet Clinical Needs. <i>Genomics and Informatics</i> , 2013, 11, 174.	0.8	9
67	Primary Intracranial Germ Cell Tumor Originating From Septum Pellucidum That Mimics Central Neurocytoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e274-e277.	1.6	10
68	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	1.3	25
69	The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1020-1027.	1.3	8
70	Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 836-844.	1.3	28
71	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	1.6	47
72	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14476-14481.	7.1	246

#	ARTICLE	IF	CITATIONS
73	Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 948-954.	1.3	12
74	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2012, 77, 288-292.	2.0	115
75	The transcriptional landscape and mutational profile of lung adenocarcinoma. <i>Genome Research</i> , 2012, 22, 2109-2119.	5.5	524
76	Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. <i>Translational Oncology</i> , 2012, 5, 430-436.	3.7	51
77	The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. <i>Translational Oncology</i> , 2012, 5, 393-IN19.	3.7	43
78	Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression Following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas. <i>Academic Radiology</i> , 2012, 19, 1353-1361.	2.5	96
79	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
80	Role of Chemotherapy on Brain Metastasis. <i>Progress in Neurological Surgery</i> , 2012, 25, 110-114.	1.3	9
81	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <i>Lung Cancer</i> , 2012, 77, 433-437.	2.0	25
82	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012, 77, 460-463.	2.0	82
83	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. <i>Lung Cancer</i> , 2012, 77, 572-577.	2.0	66
84	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. <i>Journal of Breast Cancer</i> , 2012, 15, 427.	1.9	15
85	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 3579-3586.	4.1	49
86	Influence of chemotherapy on nitric oxide synthase, indoleamine 2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. <i>Cancer Science</i> , 2012, 103, 155-160.	3.9	20
87	Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1252-1259.	4.1	84
88	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , 2012, 33, 121-129.	1.8	68
89	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	2.9	64
90	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	2.2	28

#	ARTICLE	IF	CITATIONS
91	Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 227-234.	3.0	6
92	Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2012, 44, 242-250.	3.0	17
93	The Role of Chemotherapy in Anaplastic Astrocytoma Patients. <i>Journal of Korean Neurosurgical Society</i> , 2012, 51, 199.	1.2	0
94	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	5.0	187
95	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. <i>Lung Cancer</i> , 2011, 71, 65-69.	2.0	38
96	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1474-1480.	1.1	148
97	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. <i>Journal of Thoracic Oncology</i> , 2011, 6, 905-912.	1.1	66
98	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Science</i> , 2011, 102, 1972-1976.	3.9	9
99	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. <i>Journal of Neuro-Oncology</i> , 2011, 103, 595-602.	2.9	29
100	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	2.5	32
101	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	4.1	126
102	Clinical dissection of multicentric Castleman disease. <i>Leukemia and Lymphoma</i> , 2011, 52, 1517-1522.	1.3	36
103	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
104	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 548-554.	1.3	10
105	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	1.9	48
106	Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. <i>Neuro-Oncology</i> , 2011, 13, 195-202.	1.2	51
107	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 245-252.	1.3	5
108	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	1.1	54

#	ARTICLE	IF	CITATIONS
109	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , 2010, 10, 448.	2.6	42
110	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. <i>Cancer Science</i> , 2010, 101, 1199-1203.	3.9	48
111	Definitive Radiotherapy With or Without Chemotherapy for T3-4N0 Squamous Cell Carcinoma of the Maxillary Sinus and Nasal Cavity. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 542-548.	1.3	25
112	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 427-432.	2.0	7
113	Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 758-765.	1.4	144
114	Preradiation Chemotherapy with ACNU-CDDP in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis. <i>Chemotherapy</i> , 2009, 55, 145-154.	1.6	2
115	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. <i>BMC Cancer</i> , 2009, 9, 450.	2.6	22
116	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009, 9, 73.	2.6	81
117	Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2009, 31, 1121-1128.	2.0	30
118	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 1457-1462.	5.1	69
119	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 153-160.	2.5	41
120	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009, 29, 443-449.	1.2	37
121	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009, 65, 80-84.	2.0	118
122	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009, 65, 204-207.	2.0	29
123	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 242-246.	2.0	13
124	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	10.7	571
125	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	2.5	7
126	Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. <i>Cancer</i> , 2008, 112, 1780-1786.	4.1	24

#	ARTICLE	IF	CITATIONS
127	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008, 8, 148.	2.6	64
128	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 374.	2.6	51
129	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407.	2.0	78
130	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	2.0	89
131	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. <i>Lung Cancer</i> , 2008, 62, 381-384.	2.0	20
132	Aggressiveness of Cancer-Care near the End-of-Life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 381-386.	1.3	94
133	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	1.5	54
134	Palliative chemotherapy for pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2007, 58, 112-115.	2.0	132
135	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007, 7, 203.	2.6	126
136	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007, 7, 63.	2.6	63
137	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007, 15, 631-636.	2.2	18
138	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006, 54, 201-207.	2.0	35
139	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non-Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 4232-4236.	7.0	38
140	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	1.3	18
141	An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1279-1285.	0.8	268
142	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263.	1.6	6
143	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. <i>Cellular Signalling</i> , 2005, 17, 111-119.	3.6	24
144	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 10-14.	2.3	40

#	ARTICLE	IF	CITATIONS
145	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 214-217.	1.3	6
146	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 122-128.	2.0	35
147	Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4383-4388.	7.0	74
148	l-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 2180-2195.	2.8	82
149	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480.	1.3	41
150	A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. <i>Lung Cancer</i> , 2003, 42, 227-235.	2.0	20
151	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 620-625.	1.3	3
152	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 238-243.	1.3	45